Results of Tenax Therapeutics' Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that IV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback